Estimating median overall survival of apalutamide compared to placebo in metastatic hormone-sensitive prostate cancer (mHSPC) populations: Statistical extrapolations of the TITAN study.

Authors

Neeraj Agarwal

Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Neeraj Agarwal , Anders Bjartell , Álvaro Juárez , Ronja Kerßenboom , Nolen Perualila , Peter Wigfield , Kim N. Chi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Overall survival with darolutamide vs placebo in combination with androgen-deprivation therapy (ADT) and docetaxel: A sensitivity analysis from ARASENS accounting for subsequent therapy.

First Author: Neal D. Shore

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

Oncologists’ perspectives on metastatic hormone sensitive prostate cancer management.

First Author: Patrick Heckman

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Genomic aberrations associated with overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or placebo (PBO) plus androgen deprivation therapy (ADT) in TITAN.

First Author: Neeraj Agarwal

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].

First Author: Nima Sharifi